Figures & data
Table 1 Baseline characteristics of selected studies
Figure 1 Comparison network.
Abbreviation: AML, acute myeloid leukemia.
![Figure 1 Comparison network.](/cms/asset/893c29a9-df41-4f44-a492-79d9bbd228cc/dceo_a_12162206_f0001_b.jpg)
Figure 2 Multi-stepped criteria to conduct and evaluate simulated treatment comparisons.
![Figure 2 Multi-stepped criteria to conduct and evaluate simulated treatment comparisons.](/cms/asset/faf7302c-ffe4-49f6-87fb-990ca1388f12/dceo_a_12162206_f0002_c.jpg)
Table 2 Variable selection: GLAS + LDAC vs AZA
Figure 3 Overlay of Kaplan-Meier with exponential parametrization adjusting trial IPD (A) AZA and (B) DEC populations.
Abbreviations: AZA, azacitidine; DEC, decitabine; GLAS, glasdegib; K-M, Kaplan-Meier; LDAC, low-dose cytarabine; IPD, individual patient data; OS, overall survival.
![Figure 3 Overlay of Kaplan-Meier with exponential parametrization adjusting trial IPD (A) AZA and (B) DEC populations.](/cms/asset/1507e808-d4e5-4792-b3e5-4ffc82ff73dd/dceo_a_12162206_f0003_c.jpg)
Figure 4 Overlay of Kaplan-Meier with Weibull parametrization for the weighted STC approach (A) AZA and (B) DEC populations.
Abbreviations: AZA, azacitidine; DEC, decitabine; GLAS, glasdegib; K-M, Kaplan-Meier; LDAC, low-dose cytarabine; IPD, individual patient data; OS, overall survival; STC, simulated treatment comparison.
![Figure 4 Overlay of Kaplan-Meier with Weibull parametrization for the weighted STC approach (A) AZA and (B) DEC populations.](/cms/asset/a4fe225a-b905-4c67-b7f3-a5754b2ee93a/dceo_a_12162206_f0004_c.jpg)
Table 3 ITC Cox and STC exponential model results: AZA comparison, DSU guidance
Table 4 ITC Cox and STC exponential model results: AZA comparison, weighted STC approach
Figure 5 Forest plots of exponential and Cox model estimates for (A) GLAS + LDAC versus AZA and (B) GLAS + LDAC versus DEC, DSU guidance.
Abbreviations: AZA, azacitidine; DEC, decitabine; GLAS, glasdegib; ITC, indirect treatment comparison; LDAC, low-dose cytarabine; STC, simulated treatment comparison.
![Figure 5 Forest plots of exponential and Cox model estimates for (A) GLAS + LDAC versus AZA and (B) GLAS + LDAC versus DEC, DSU guidance.](/cms/asset/22281dcc-4674-4c58-9a3a-101843f6a33c/dceo_a_12162206_f0005_c.jpg)
Figure 6 Forest plots of exponential and Cox model estimates for (A) GLAS + LDAC versus AZA and (B) GLAS + LDAC versus DEC, weighted STC approach.
Abbreviations: AZA, azacitidine; DEC, decitabine; GLAS, glasdegib; HR, hazard ratio; ITC, indirect treatment comparison; LDAC, low-dose cytarabine; STC, simulated treatment comparison.
![Figure 6 Forest plots of exponential and Cox model estimates for (A) GLAS + LDAC versus AZA and (B) GLAS + LDAC versus DEC, weighted STC approach.](/cms/asset/292e042b-e159-4c8f-949f-0d94a9ce44f3/dceo_a_12162206_f0006_c.jpg)
Table 5 Inclusion of covariates, GLAS + LDAC vs DEC
Table 6 ITC Cox and STC exponential model results: DEC comparison, DSU guidance
Table 7 ITC Cox and STC exponential model results: DEC comparison, weighted STC approach